FDA limits use of tolvaptan (Samsca) due to liver-injury risk | theheart.org
Friday, May 3, 2013 - 06:00
in Health & Medicine
ilver Spring, MD - The US Food and Drug Administration (FDA) today announced that it has placed new restrictions on the use of tolvaptan (Samsca, Otsuka American Pharmaceutical) because of a risk for serious and potentially fatal liver injury [1].